Patents Represented by Attorney Carol G. Canter

Find this attorney in the Justia Lawyer Directory

  • Gal operon of streptomyces
    Patent number: 5242809
    Abstract: A recombinant DNA molecule comprising the Streptomyces gal operon galK gene; galE gene; galT gene; P1 promoter, P2 promoter, P2 promoter expression unit; P1 promoter regulated region; or the entire Streptomyces gal operon.
    Type: Grant
    Filed: October 27, 1992
    Date of Patent: September 7, 1993
    Assignee: SmithKline Beecham Corporation
    Inventors: Craig W. Adams, Mary E. Brawner, James A. Fornwald, Francis J. Schmidt
  • Tumor cell growth-inhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes
    Patent number: 5037812
    Abstract: Pharmaceutical compositions and a method for inhibiting the growth of tumor cells by administering a tumor cell growth-inhibiting amount of a bis[bis (diphenylphosphino)hydrocarbon]-, bis[bis(diethylphsophino) hydrocarbon]-, bis[bis(diphenylphosphine-deithylphosphino) hydrocarbon]gold(I), silver(I) or copper(I) complex or a tris[bis(diphenylphosphino)ethane] dicopper(I) complex to an animal afflicted with said tumor cells.
    Type: Grant
    Filed: June 11, 1986
    Date of Patent: August 6, 1991
    Assignee: SmithKline Beckman Corporation
    Inventors: Susan J. Berners-Price, Randall K. Johnson, Christopher K. Mirabelli, Peter J. Sadler
  • Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
    Patent number: 5004758
    Abstract: Water soluble camptothecin analogs, pharmaceutical compositions comprising such analogs, and a method of inhibiting the growth of tumor cells sensitive to such analogs in an animal in need thereof.
    Type: Grant
    Filed: November 2, 1988
    Date of Patent: April 2, 1991
    Assignee: SmithKline Beecham Corporation
    Inventors: Jeffrey C. Boehm, Sidney M. Hecht, Kenneth G. Holden, Randall K. Johnson, William D. Kingsbury
  • Immunomodulatory azaspiranes
    Patent number: 4963557
    Abstract: A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an effective amount of an azaspirane derivative, a method of treating an animal in need of immunomodulation which comprises administering to such animal an effective amount of an azaspirane derivative, and certain azaspirane derivatives.
    Type: Grant
    Filed: September 13, 1988
    Date of Patent: October 16, 1990
    Assignee: SmithKline Beecham Corporation
    Inventors: Alison M. Badger, Elaine N. Cheeseman, Michael J. DiMartino, James W. Dorman, Christopher K. Mirabelli, Donald H. Picker, David A. Schwartz
  • "2-pyridyl and 4-pyridyl phosphine gold (I) anti tumor complexes"
    Patent number: 4902675
    Abstract: 2-pyridyl and 4-pyridyl phosphine gold compounds of the formula: ##STR1## and 2-pyridyl phosphine gold compounds of the formula: ##STR2## and pharmaceutical compositions containing an effective, tumor cell growth-inhibiting amount of such a compound.
    Type: Grant
    Filed: April 4, 1986
    Date of Patent: February 20, 1990
    Assignee: SmithKline Beckman Corporation
    Inventors: David T. Hill, Randall K. Johnson
  • Antitumor compounds
    Patent number: 4857549
    Abstract: Compounds, pharmaceutical compositions and a method for treating tumors by administering an effective tumor cell growth-inhibiting amount of a .alpha.,.omega.-bis(disubstitutedphosphino)hydrocarbon compound or a [.alpha.,.omega.-bis(disubstitutedphosphino)hydrocarbon] digold(I), digold(III, disiliver(I) or dicopper(I) complex to an animal afflicted by such tumor cells.
    Type: Grant
    Filed: February 26, 1988
    Date of Patent: August 15, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: David T. Hill, Randall K. Johnson, Christopher K. Mirabelli
  • Process for the extraction and purification of proteins from culture media producing them
    Patent number: 4857317
    Abstract: The process is applicable to the supernatant of engineered yeast cells disrupted in the presence of a non-ionic detergent; it comprises the precipitation of contaminants by polyethylene glycol and the treatment of this latter supernatant with either a bivalent metal cation or, after eventual ultrafiltration, with ammonium sulfate.
    Type: Grant
    Filed: April 27, 1987
    Date of Patent: August 15, 1989
    Assignee: SmithKline Biologicals
    Inventors: Frans V. Wijnendaele, Daniel Gilles, Guy Simonet
  • Inhibition of the 5-lipoxygenase pathway utilizing certain 2,2'-alkyldiyl bis(thio)bis-imidazoles and derivatives
    Patent number: 4847270
    Abstract: Novel compounds, pharmaceutical compositions and a method of inhibiting the 5-lipoxygenase products in an animal in need thereof which comprises administering an effective, 5-lipoxygenase pathway inhibiting amount of a 2,2'-[1,2-ethanediylbis-(thio)]-bis-1H-imidazole or 2,2'-[1,3-propan-2-onediylbis-(thio)]bis-1H-imidazole, or a pharmaceutically acceptable salt thereof, to such animal.
    Type: Grant
    Filed: November 10, 1987
    Date of Patent: July 11, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, David T. Hill
  • Immunomodulation
    Patent number: 4803072
    Abstract: An immunomodulating pharmaceutical composition comprising an effective, leukocyte interferon production inducing amount of NS1 and a pharmaceutically acceptable carrier or diluent; and a method of modulating the immune response in a human or other animal in need thereof by inducing the production of leukocyte IFN which comprises administering an effective amount of NS1 to such human or animal.
    Type: Grant
    Filed: September 10, 1986
    Date of Patent: February 7, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Barbara J. Dalton, Robert C. Rees
  • 1.4-dihydro-4-pyridyl-substituted imidazo (2,1-b) thiazoles and the corresponding thiazines.
    Patent number: 4803279
    Abstract: 6-Aryl-2,3-dihydroimidazo[2,1-b]thiazoles and corresponding thiazines act as nucleophiles, either directly or in the form of Grignard reagents, with N-acylpyridinium salts to produce new 6-aryl-5-(N-acyl-1,4-dihydro-4-pyridyl)-2,3-dihydroimidazo-[2,1-b]thiazole s and corresponding thiazines. These are oxidized to give the corresponding pyridyl-substituted imidazo[2,1-b]thiazoles and thiazines, which are active as inhibitors of the 5-lipoxygenase pathway of arachidonic acid metabolism.
    Type: Grant
    Filed: April 28, 1986
    Date of Patent: February 7, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, Ivan Lantos, Michael A. McGuire, Lendon N. Pridgen, Herbert B. Winicov
  • Inhibition of interleukin-1 production by monocytes and/or macrophages
    Patent number: 4794114
    Abstract: A method of inhibiting the 5-lipoxygenase pathway in an animal in need thereof which comprises administering an effective, 5-lipoxygenase pathway inhibiting amount of a diaryl-substituted imidazole fused to a thiazole pyrrolidine, thiazide or piperidine ring to such animal.
    Type: Grant
    Filed: June 17, 1987
    Date of Patent: December 27, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, Don E. Griswold, Nabil Hanna, John C. Lee
  • Plasmids from nocardia
    Patent number: 4791064
    Abstract: A plasmid naturally present in N. orientalis can be used as a vector for cloning or expression in Actinomycetales and to derive other vectors.
    Type: Grant
    Filed: June 12, 1985
    Date of Patent: December 13, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Louis R. Fare, Yong K. Oh, Dean P. Taylor, Jenifer B. Widger
  • Inhibition of interleukin-1 by monocytes and/or macrophages
    Patent number: 4780470
    Abstract: A method of inhibiting the production of interleukin-1 by monocytes in a human in need thereof which comprises administering to such human an effective interleukin-1 production inhibiting amount of a 4,5-diaryl-2(substituted)imidazole.
    Type: Grant
    Filed: August 19, 1986
    Date of Patent: October 25, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, Don E. Griswold, Nabil Hanna, John C. Lee
  • Inhibition of interleukin-1 production by monocytes and/or macrophages
    Patent number: 4778806
    Abstract: A method of inhibiting the production of interleukin-1 by monocytes and/or macrophages in a human in need thereof which comprises administering to such human an effective interleukin-1 production inhibiting amount of a 2-2'-[1,3-propan-2-onediyl-bis(thio)]bis-1H-imidazole or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 19, 1986
    Date of Patent: October 18, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, Don E. Griswold, Nabil Hanna, John C. Lee
  • Antitumor pharmaceutical compositions and methods for treating tumors employing .alpha.,.omega.-bis(disubstitutedphosphino)hydrocarbon derivatives or [.alpha., .omega.-bis(disubstitutedphosphino)hydrocarbon] d i
    Patent number: 4766226
    Abstract: Antitumor pharmaceutical compositions and methods for treating tumors employing .alpha.,.omega.-bis(disubstitutedphosphino)hydrocarbon derivatives or [.alpha.,.omega.-bis(disubstituted phosphino)hydrocarbon] digold(I), digold(III), disilver(I), and dicopper(I) derivatives are disclosed.
    Type: Grant
    Filed: April 2, 1985
    Date of Patent: August 23, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: David T. Hill, Randall K. Johnson, Christopher K. Mirabelli
  • Pharmaceutical compositions containing di-gold phosphine
    Patent number: 4764509
    Abstract: Pharmaceutical compositions containing an effective, tumor cell growth-inhibiting amount of such a compound, and a method for treating tumor cells sensitive to such a di-gold phosphine compound which comprises administering a tumor cell growth-inhibiting amount of such a compound to an animal afflicted by said tumor cells.
    Type: Grant
    Filed: August 17, 1987
    Date of Patent: August 16, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: David T. Hill, Randall K. Johnson
  • Tetraphosphine-coordinated gold(I) complexes
    Patent number: 4758589
    Abstract: Tetraphosphine-coordinated gold (I) compounds, pharmaceutical compositions containing an effective, tumor cell growth-inhibiting amount of such a compound, and a method of treating tumor cells sensitive to such a compound which comprises administering a tumor cell growth-inhibiting amount of such a compound to an animal afflicted by said tumor cells.
    Type: Grant
    Filed: February 2, 1987
    Date of Patent: July 19, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: David T. Hill, Randall K. Johnson
  • Certain bio-(bi-2-thienyl or 2-furyl phosphino) lower alkanes having anti-tumor properties
    Patent number: 4755611
    Abstract: Heterocyclic phosphine compounds, pharmaceutical compositions containing an effective, tumor cell growth-inhibiting amount of such a compound, and a method for treating tumor cells sensitive to such a compound which comprises adminstering a tumor cell growth-inhibiting amount of such a compound to an animal afflicted by said tumor cells.
    Type: Grant
    Filed: August 11, 1987
    Date of Patent: July 5, 1988
    Assignee: SmithKline Beckman Corporation
    Inventor: David T. Hill
  • Inhibition of the 5-lipoxygenase pathway
    Patent number: 4751310
    Abstract: Compounds having the formula ##STR1## wherein n is 0 or 1, R.sup.2 through R.sup.9 are H or C.sub.1-2 alkyl, and X is pyridyl or mono- or disubstituted phenyl are useful in the preparation of the compounds which inhibit the 5-lipoxygenase pathway.
    Type: Grant
    Filed: September 22, 1987
    Date of Patent: June 14, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, Nabil Hanna
  • 2,2-alkyldiylbis(thio)bis(imidazoles) useful for inhibition of the 5-lipoxygenase pathway
    Patent number: 4728656
    Abstract: Novel compounds, pharmaceutical compositions and a method of inhibiting the 5-lipoxygenase products in an animal in need thereof which comprises administering an effective, 5-lipoxygenase pathway inhibiting amount of a 2,2'-[1,2-ethanediylbis-(thio)]-bis-1H-imidazole or 2,2'-[(1,3-propan-2-onediylbis-(thio)]bis-1H-imidazole, or a pharmaceutically acceptable salt thereof, to such animal.
    Type: Grant
    Filed: April 28, 1986
    Date of Patent: March 1, 1988
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, David T. Hill